PER

4.94%

8.5¢ percheron therapeutics limited

Here’s the thingLarge Funds and Pharmas waiting on the...

First 4254 Last

Share
Profile

Follow
itsagas

13,075 Posts.

1362

21/10/21

09:38

Post #: 56958251
Share

Originally posted by mephistophles: ↑

Hey @George1972 @samfiodiving,

My opinion largely irrelevant (~500k shares and not as cluey as you lot), but I have to agree with a large deal being the desired outcome here. I'm not particularly fussed if there's a CR in the 30-40c region, although George makes an excellent point re risk mitigation that's given me some pause.

Anyway, that's not the point of this message...

I'm actually quite curious as to what you guys imagine happening with the potential PRV, if there is indeed a deal waiting?

In my limited (hence querying) experience, these are usually designated to be sold and the proceeds split evenly, but I've only seen this in deals where the big-fish is taking complete rights for drug A in region X. I don't imagine us doing a deal like that with ATL1102 UNLESS IT'S ABSOLUTELY MASSIVE, because mgmt know that we're potentially sitting on a platform drug?

i.e. A deal would more likely be centred around ATL1102, specifically for the treatment of DMD, in regions x and y?

Not sure if that might change anything with respect to the usual "split the proceeds from the sale of the PRV" line?

Cheers.

p.s. Tangentially, it could be quite interesting if [select-your-partner] runs the trial and we get access to the data for ROW. Apparently Asia (particularly Japan) is emerging as a profitable rare disease market. I assume we'd all like to see Aussie boys benefit from ATL1102 ASAP too

Expand

Here’s the thing

Large Funds and Pharmas waiting on the sidelines
EMA approval validates Atl1102
A 12 month study will end up in commercialisation$$

Now: A 12 month study with the same end points already proven in our last DMD trial..

No Brainer

Thats all everyone is waiting for Funds Pharmas etc

Share Price won’t be crawling.. will go up in 5/10 cents lots ..

Whatever you do.. Don’t sell!
Cr will only help expand the Anp pipeline…$$

ANP Price at posting: 29.0¢ Sentiment: Buy Disclosure: Held
16 Upvote

0 Great analysis

Reply

Top Stories

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

RCE

Recce's R327 found effective against E.coli during clinical trial

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Microcap Wrap: 5 explorers with news out today

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

There are more pages in this discussion • 1,652 more messages in this thread...

First 4254 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 8.5¢		Change 0.004(4.94%)		Mkt cap ! $76.63M

Open	High	Low	Value	Volume
8.1¢	8.5¢	8.1¢	$46.54K	563.7K

Buyers (Bids)

No.	Vol.	Price($)
2	164616	8.1¢

Sellers (Offers)

Price($)	Vol.	No.
8.5¢	100110	1

View Market Depth

No.	Vol.	Price($)
2	164616	0.081
5	215500	0.080
1	250000	0.079
3	71500	0.078
2	121300	0.077

Price($)	Vol.	No.
0.085	100110	1
0.087	125000	1
0.089	102263	2
0.090	146175	1
0.091	108000	1

Last trade - 15.55pm 28/06/2024 (20 minute delay)

PER (ASX) Chart

Here’s the thingLarge Funds and Pharmas waiting on the...

Ava Risk Group expands US presence with A$0.7M Substation Deal

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Recce's R327 found effective against E.coli during clinical trial

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Microcap Wrap: 5 explorers with news out today

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Here’s the thingLarge Funds and Pharmas waiting on the...

Top Stories

Ava Risk Group expands US presence with A$0.7M Substation Deal

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Recce's R327 found effective against E.coli during clinical trial

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Microcap Wrap: 5 explorers with news out today

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News